BACKGROUND: We sought to determine whether markers of systemic inflammation are associated with the presence of moderate/severe obstructive sleep apnea (OSA) and whether this association differs based on HIV and HIV treatment status. METHODS: HIV-uninfected men (HIV-; n=60), HIV-infected men receiving HAART (HIV+/HAART; n=58) and HIV-infected men not receiving HAART (HIV+/no HAART; n=41) underwent polysomnograpy and measurement of plasma levels of tumour necrosis factor (TNF)-α, soluble TNF-α receptors I and II (sTNFRI and sTNFRII) and interleukin (IL)-6. The relationship between moderate/severe OSA (respiratory disturbance index ≥15 apnea/hypopnea events/h) and inflammatory markers was assessed with multivariable regression models. RESULTS: Compared with the HIV- men, HIV+/HAART men and HIV+/no HAART men had higher levels of TNF-α, sTNFRI and sTNFRII, independent of age, race, smoking status, obstructive lung disease (OLD) and body mass index (BMI). Moderate/severe OSA was present in 48% of the sample (HIV- 57%; HIV+/HAART 41%; HIV+/no HAART 44%). Among the HIV+/no HAART men, but not in the other groups, TNF-α, sTNFRII and IL-6 levels were higher in those with moderate/severe OSA compared to men with no/mild OSA after adjustment for age, race, smoking status, OLD and BMI. Within this group, the association of high TNF-α concentrations with moderate/severe OSA was also independent of CD4(+) T-cell count and plasma HIV RNA concentration. CONCLUSIONS: Compared with HIV+/HAART men and HIV- men, markers of systemic inflammation were higher in HIV+/no HAART men. In these men, TNF-α was significantly related to OSA, independent of HIV-related covariates.
BACKGROUND: We sought to determine whether markers of systemic inflammation are associated with the presence of moderate/severe obstructive sleep apnea (OSA) and whether this association differs based on HIV and HIV treatment status. METHODS:HIV-uninfectedmen (HIV-; n=60), HIV-infectedmen receiving HAART (HIV+/HAART; n=58) and HIV-infectedmen not receiving HAART (HIV+/no HAART; n=41) underwent polysomnograpy and measurement of plasma levels of tumour necrosis factor (TNF)-α, soluble TNF-α receptors I and II (sTNFRI and sTNFRII) and interleukin (IL)-6. The relationship between moderate/severe OSA (respiratory disturbance index ≥15 apnea/hypopnea events/h) and inflammatory markers was assessed with multivariable regression models. RESULTS: Compared with the HIV- men, HIV+/HAART men and HIV+/no HAART men had higher levels of TNF-α, sTNFRI and sTNFRII, independent of age, race, smoking status, obstructive lung disease (OLD) and body mass index (BMI). Moderate/severe OSA was present in 48% of the sample (HIV- 57%; HIV+/HAART 41%; HIV+/no HAART 44%). Among the HIV+/no HAART men, but not in the other groups, TNF-α, sTNFRII and IL-6 levels were higher in those with moderate/severe OSA compared to men with no/mild OSA after adjustment for age, race, smoking status, OLD and BMI. Within this group, the association of high TNF-α concentrations with moderate/severe OSA was also independent of CD4(+) T-cell count and plasma HIV RNA concentration. CONCLUSIONS: Compared with HIV+/HAART men and HIV- men, markers of systemic inflammation were higher in HIV+/no HAART men. In these men, TNF-α was significantly related to OSA, independent of HIV-related covariates.
Authors: P Brazille; N Dereuddre-Bosquet; C Leport; P Clayette; O Boyer; J-L Vildé; D Dormont; O Benveniste Journal: Clin Exp Immunol Date: 2003-02 Impact factor: 4.330
Authors: Deborah L Regidor; Roger Detels; Elizabeth C Breen; Daniel P Widney; Lisa P Jacobson; Frank Palella; Charles R Rinaldo; Jay H Bream; Otoniel Martínez-Maza Journal: AIDS Date: 2011-01-28 Impact factor: 4.177
Authors: A N Vgontzas; D A Papanicolaou; E O Bixler; A Kales; K Tyson; G P Chrousos Journal: J Clin Endocrinol Metab Date: 1997-05 Impact factor: 5.958
Authors: Todd T Brown; Susheel P Patil; Lisa P Jacobson; Joseph B Margolick; Alison M Laffan; Rebecca J Godfrey; Jacquett R Johnson; Lisette M Johnson-Hill; Sandra M Reynolds; Alan R Schwartz; Philip L Smith Journal: Antivir Ther Date: 2010
Authors: Alan R Schwartz; Susheel P Patil; Samuel Squier; Hartmut Schneider; Jason P Kirkness; Philip L Smith Journal: J Appl Physiol (1985) Date: 2009-10-29
Authors: Michael D Wirth; Jason R Jaggers; Wesley D Dudgeon; James R Hébert; Shawn D Youngstedt; Steven N Blair; Gregory A Hand Journal: AIDS Behav Date: 2015-06
Authors: K M Kunisaki; K M Akgün; D A Fiellin; C L Gibert; J W Kim; D Rimland; M C Rodriguez-Barradas; H K Yaggi; K Crothers Journal: HIV Med Date: 2014-09-17 Impact factor: 3.180
Authors: Christopher N Schmickl; Naa-Oye Bosompra; Pamela N DeYoung; Dillon Gilbertson; Jeremy E Orr; Atul Malhotra; Igor Grant; Sonia Ancoli-Israel; Maile Karris Young; Robert L Owens Journal: J Clin Sleep Med Date: 2022-07-01 Impact factor: 4.324
Authors: Jeremy E Orr; Bradley A Edwards; Christopher N Schmickl; Maile Karris; Pamela N DeYoung; Chantal Darquenne; Rebecca Theilmann; Sonia Jain; Atul Malhotra; Charles B Hicks; Robert L Owens Journal: J Appl Physiol (1985) Date: 2021-10-21
Authors: L B Mulenga; P Musonda; L Chirwa; M Siwingwa; A Mweemba; S Suwilanji; S Fwoloshi; H Phiri; D Phiri; P L Mulenga; T Chisenga; R Nsakanya; A Shibemba; J Todd; S Nzala; T Kaile; C Kankasa; L Hachaambwa; C Claassen; I Sikazwe; J R Koethe; E Sinkala; D C Heimburger; C W Wester Journal: J Infect Dis Ther Date: 2019-08-16
Authors: Cecilia M Shikuma; Lindsay Kohorn; Robert Paul; Dominic C Chow; Kalpana J Kallianpur; Maegen Walker; Scott Souza; Louie Mar A Gangcuangco; Beau K Nakamoto; Francis D Pien; Timothy Duerler; Linda Castro; Lorna Nagamine; Bruce Soll Journal: HIV Clin Trials Date: 2018-11-19
Authors: Davide De Francesco; Caroline A Sabin; Alan Winston; Patrick W G Mallon; Jane Anderson; Marta Boffito; Nicki D Doyle; Lewis Haddow; Frank A Post; Jaime H Vera; Memory Sachikonye; Susan Redline; Ken M Kunisaki Journal: AIDS Date: 2021-06-01 Impact factor: 4.632
Authors: Leonard Ngarka; Joseph Nelson Siewe Fodjo; Esraa Aly; Willias Masocha; Alfred K Njamnshi Journal: Front Immunol Date: 2022-01-13 Impact factor: 8.786
Authors: Sumanth Karamchand; Rory Leisegang; Michael Schomaker; Gary Maartens; Lourens Walters; Michael Hislop; Joel A Dave; Naomi S Levitt; Karen Cohen Journal: Medicine (Baltimore) Date: 2016-03 Impact factor: 1.889